Analysis of the ongoing clinical trials evaluating CAR-T cells revealed that CD19 and BCMA are the most frequently used antigens for CAR-T therapies against hematological malignancies, whereas, for solid tumors, CAR-T cells are directed against, e.g., mesothelin, carcinoembryonic antigen (CEA), Mucin 1 (MUC1), HER2, EGFR, and glypican-3 (GPC3) [171]. This evidence concerns the gene GPC3 and hematologic disorder.